US 12,128,024 B2
Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
Richard Schlegel, Rockville, MD (US); Dan-Paul Hartmann, Bethesda, MD (US); and Astrid Baege, Zurich (CH)
Assigned to Georgetown University, Washington, DC (US)
Filed by GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed on Oct. 16, 2020, as Appl. No. 17/072,726.
Application 13/777,244 is a division of application No. 13/179,978, filed on Jul. 11, 2011, granted, now 8,394,849, issued on Mar. 12, 2013.
Application 13/179,978 is a division of application No. 10/545,356, granted, now 7,989,491, issued on Aug. 2, 2011, previously published as PCT/US2004/004067, filed on Feb. 12, 2004.
Application 17/072,726 is a continuation of application No. 16/152,686, filed on Oct. 5, 2018, abandoned.
Application 16/152,686 is a continuation of application No. 15/292,511, filed on Oct. 13, 2016, abandoned.
Application 15/292,511 is a continuation of application No. 14/605,499, filed on Jan. 26, 2015, abandoned.
Application 14/605,499 is a continuation of application No. 13/777,244, filed on Feb. 26, 2013, granted, now 8,940,787, issued on Jan. 27, 2015.
Prior Publication US 2021/0038565 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 493/18 (2006.01); A61K 31/335 (2006.01); A61K 31/357 (2006.01); A61K 31/365 (2006.01); A61K 31/366 (2006.01); A61K 45/06 (2006.01); A61P 31/20 (2006.01)
CPC A61K 31/366 (2013.01) [A61K 31/335 (2013.01); A61K 31/357 (2013.01); A61K 31/365 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); C07D 493/18 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating a Human papillomavirus (HPV)-induced lesion at a genital site or an anal site in a subject in need thereof, comprising administering a therapeutically effective amount of an artemisinin-related compound to the subject, wherein the artemisinin-related compound is selected from the group consisting of artemisinin, dihydroartemisinin, artemether, arteether, artesunate, artelinic acid, and dihydroartemisinin propyl carbonate and wherein the lesion is pre-malignant or malignant.